Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersInternal Medicine Physician in Newburgh, IN
NPI: 1336142728Primary Practice Location
ENCOMPASS HEALTH DEACONESS REHABILITATION HOSPITAL
9355 Warrick Trl, Newburgh, IN
Primary Employer
Deaconess Clinic I
deaconess.com
HQ Phone
Get M.D. Mohammed's Phone Numberphone_androidMobile
Get M.D. Mohammed's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIN State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 93010Routine electrocardiogram (EKG) using at least 12 leads with interpretation and report | 460 | 515 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 351 | 755 |
| 3 | G0439Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 261 | 261 |
| 4 | G0008Administration of influenza virus vaccine | 94 | 95 |
| 5 | 90694Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | 87 | 88 |
Lead Sponsor: GlaxoSmithKline
Intervention / Treatment: BIOLOGICAL: Placebo, BIOLOGICAL: RSVPreF3 OA vaccine
Lead Sponsor: GlaxoSmithKline
Collaborators: PPD Development, LP
Intervention / Treatment: DRUG: Placebo, BIOLOGICAL: Mepolizumab
Lead Sponsor: Sanofi Pasteur, a Sanofi Company
Collaborators: GlaxoSmithKline
Intervention / Treatment: BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03, BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4
